From an approval for a disease affecting 900 people worldwide to a new drug class in multiple myeloma and a $322 million ...
Chai Discovery has announced a collaboration with Bristol Myers Squibb to advance the discovery of therapeutic antibodies using artificial intelligence.
K2 Therapeutics CEO Ying Huang discusses why government investment and US-trained returnees have made China's biotech ...
However, in a conversation with Norstella’s VP of thought leadership Dan Chancellor, he explained that pipeline creation has ...
A partnership roundup covers deals from IntraGel Therapeutics/UroGen Pharma and Lupin/Tenpoint Therapeutics, FDA approves ...
Rohit Tripathi, VP of Industry Strategy at RELEX, lays out the five signals that he believes can measure if the tariff policy ...
UroGen Pharma has invested in IntraGel Therapeutics and secured an exclusive option to license Tumocure, and Lupin's ...
Pharmaceutical reshoring is constrained by supplier qualification, process validation, FDA compliance readiness, workforce ...
FDA approval in adult FOP targets disease-driving Activin A biology, addressing progressive heterotopic ossification that ...
President Trump has reportedly selected White House Domestic Policy Council deputy director Heidi Overton as his nominee for ...
How drug pricing, tariffs, and manufacturing decisions are becoming connected. For years, pharmaceutical companies could ...
Heidi Overton, a UNM-trained physician with Johns Hopkins general surgery training, was selected for FDA commissioner after ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results